Trial Profile
A retropsective study evaluating efficacy of tocilizumab therapy for therapy-refractory uveitis associated with juvenile idiopathic arthritis (JIA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2016
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis; Uveitis
- Focus Therapeutic Use
- 18 Oct 2016 New trial record
- 15 Sep 2016 Results published in The Journal of Rheumatology